TAK-165

07/05/2022 - "Moreover, the SKBR3 orthotopic xenograft model confirmed that compound Q7j was more effective than Mubritinib in inhibiting the proliferation of cancer cells. "
01/01/2020 - "The effect of mubritinib as an anti-cancer drug is therefore only due to its activity against mitochondria. "
01/01/2020 - "Recent data has suggested that an anti-cancer drug called mubritinib has off-target effects on the compartments within cells that provide the cell with most of their energy, the mitochondria. "
01/01/2018 - "Finally, we showed that the combination of TAK-165 and AC220 induced cell death in cancer cells through the activation of chaperone-mediated autophagy. "
01/01/2018 - "We showed that TAK-165 and AC220 act synergistically to downregulate key signaling pathways and potently induce cancer cell death. "

11/17/2020 - "Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism."

01/01/2019 - "Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia."

01/01/2019 - "A selective ErbB2 tyrosine kinase inhibitor, mubritinib, impaired wound closure and decreased cyclin D1 expression in healthy HAECs, with less effect on cells from asthmatic patients, supporting diminished activity in asthmatic patients. "

05/01/2006 - "We therefore investigated the antitumor effect of TAK-165 on these urological cancer cells. "